74 results about "Propofol" patented technology

Systems and methods for controlling anesthetic-mediated unconsciousness in a patient are disclosed. An electroencephalogram (EEG) of a patient under a GABAergic-anesthetic may be recorded using EEG electrodes. Unconsciousness maintained by GABAergic anesthetics, such as propofol, propanidid, and / or sevoflurane, is characterized by slow-delta oscillations (0.3-4 Hz) and alpha oscillations (8-14 Hz) that may be viewed in an electroencephalogram (EEG). An alpha modulation index and a slow modulation index may be computed to characterize the level of unconsciousness of the patient and set a desired level of unconsciousness. The system may automatically or manually adjust the infusion rate of the anesthetic to achieve the desired level of unconsciousness.

The invention relates to a deep learning method-based pharmacokinetics-pharmacodynamics and reinforcement learning-based propofol administration method and application thereof, a PKPD model is used for simulating the metabolic process of propofol in a human body, and a time dependency relationship and dynamics continuous information are extracted through LSTM and Neural OED; then a nonlinear relation between the propofol drug effect concentration and a clinically observed anesthesia depth index BIS is established through a Kan network, mapping between monitoring information and the anesthesia depth in an operation is rapidly established, a strategy is adjusted in time according to environment changes, and the method is suitable for processing non-standardized complex problems and has good application prospects. And the dosage and the administration scheme of the medicine are individually adjusted, so that the treatment effect is improved.

The invention discloses a propofol blood drug concentration detection sampling collection system and method, comprising: a positioning base structure; a sample storage structure to be tested, and the sample storage structure to be tested is set as a continuously translatable sample to be tested pool; a detection sample storage structure, and the detection sample storage structure is set as a continuously translatable sample detection pool; a displacement drive structure, and the displacement drive structure has a corresponding horizontal and vertical linear kinetic energy output end; an injector structure, which is fixed to the linear kinetic energy output end of the displacement drive structure; a suction and blowing air pump structure, and the suction and blowing air pump structure has an air extraction end and an air blowing end connected to the injector structure through a pipeline. The invention solves the technical problems that the operation process of the prior art for real-time monitoring of propofol concentration in plasma depends on manual blood collection and transfer, the operation process is time-consuming and laborious, the overall automation degree is low, the continuity is poor, there is a blank period, and it is difficult to maintain efficient and continuous real-time monitoring of propofol concentration in plasma.

The invention discloses a dexmedetomidine and propofol combined reagent and a combination method, and relates to the technical field of combined use of anesthetic drugs. According to the method, firstly, dexmedetomidine is subjected to intravenous pump injection within 5-15 minutes according to the dosage of 0.5-1.0 mu g / kg, propofol is given within 2 minutes after the dexmedetomidine is subjected to general anesthesia, and the dosage of the propofol can be reduced by 10%-50% compared with that of propofol which is independently used. Through pretreatment of dexmedetomidine, the anesthetic effect of propofol can be enhanced, adverse reactions such as blood pressure drop and respiratory depression can be effectively reduced, and anesthetic safety and controllability are improved. The combined reagent comprises independent containers for respectively loading the dexmedetomidine injection and the propofol emulsion, and can be packaged by adopting a double-cavity pre-filled injector, and sequential injection is realized through a controllable opening mechanism, so that unstable emulsification and titer change caused by physical mixing of medicines are avoided.

The invention provides a method for detecting related substances of an emtricitabine, propofol and tenofovir compound preparation. Specifically, the invention provides a high performance liquid chromatography detection method for the emtricitabine, propofol and tenofovir compound preparation related substances, and the method can realize rapid, simple and accurate separation and detection of the emtricitabine, propofol fumarate and tenofovir related substances. Therefore, the quality control requirements of the emtricitabine, propofol and tenofovir compound preparation are met.

The invention relates to the technical field of pharmaceutical analysis, and particularly discloses a high performance liquid chromatography-mass spectrometry tandem method (HPLC-MS / MS) for detecting a genotoxic impurity L-alanine isopropyl ester in an emtricitabine-propofol tenofovir tablet. By optimizing chromatographic column selection, a mobile phase gradient elution procedure and mass spectrometric detection parameters, the method realizes exclusive, sensitive and accurate detection of the L-isopropyl alanine. The methodological verification result shows that the detection limit is 1.00 ng / mL, the quantification limit is 2.00 ng / mL, the linear range is 2.00-100.00 ng / mL (the correlation coefficient r is equal to 0.9994), the recovery rate is stabilized between 92% and 98%, and the precision and repeatability are good. The detection method has the advantages of high sensitivity and strong selectivity, is suitable for quality control of emtricitabine propofol tenofovir tablets, meets the control requirements of ICH M7 guide on genotoxic impurities, and has good practicability and popularization value.

The present invention relates to a continuous process for the preparation of a highly pure compound of formula III i.e. propofol, suitable for industrial or pharmaceutical use:

The invention discloses a serum protein removal method and a rapid propofol detection method, and relates to the technical field of propofol detection.The serum protein removal method comprises the steps that a serum sample and 50% trichloroacetic acid are ultrasonically mixed to be uniform and centrifuged, and supernate without protein is obtained; the rapid propofol detection method comprises the following steps: S1, adopting the serum protein removal method; s2, ultrasonically and uniformly mixing the supernate with an organic solvent, and centrifuging to obtain an organic phase containing propofol; and S3, mixing the organic phase with a molecular probe and an alkali solution for reaction and color development, and measuring an absorbance value. According to the scheme, the concentration of the propofol in the serum can be accurately and rapidly detected.

Pharmaceutical combinations of etomidate derivatives and propofol and pharmaceutical compositions thereof for use in anesthesia, sedation and / or hypnosis of animals or humans. The pharmaceutical composition of the etomidate derivative and the propofol or the pharmaceutical composition of the etomidate derivative and the propofol shows an excellent synergistic effect compared with independent administration and combined administration.

The invention provides liquid compositions in the form of physically stable emulsions comprising a semifluorinated alkane. The semifluorinated alkane is comprised in the dispersed phase, which may also include an active pharmaceutical ingredient. One of the preferred active ingredients is propofol. The compositions are optionally heat sterilisable and can be used for pharmaceutical or cosmetic product applications, and administered topically, intravenously, or via other routes.

The present invention discloses a nanoprobe and portable detection device for detecting propofol in serum, relating to the field of biomedical detection technology. The nanoprobe comprises UCNPs and a diazonium salt, wherein the diazonium salt is formed by the reaction of p-aminobenzenesulfonic acid and sodium nitrite. The nanoprobe uses the diazonium salt as a propofol recognition unit, and the UCNPs as an energy donor. In the presence of propofol, the nanoprobe can cause luminescence quenching. The rapid and specific response between the diazonium salt and propofol enables rapid, sensitive, and visual detection of propofol.

An antibody for binding to propofol is provided. Also provided is an immunoassay for assaying propofol and a rapid, point-of-care immune-biosensor for propofol.

The utility model relates to the technical field of medicine pumping devices, and discloses a device for rapidly pumping a large amount of medicine at a time, which comprises a base, a plurality of medicine pumping devices and a plurality of medicine pumping devices, and is characterized in that the upper surface of the base is provided with a mounting frame; the medicine placing tray is arranged on the upper surface of the base, and medicine placing grooves are evenly distributed in the upper surface of the medicine placing tray; and the mounting grooves are formed in the two sides of the upper surface of the base, first hydraulic telescopic rods are mounted in the mounting grooves correspondingly, and a fixing frame is arranged above the base. A first hydraulic telescopic rod is started to drive a needle tube of an injector to be inserted into a propofol container, a second hydraulic telescopic rod is started to drive a mounting frame to move downwards, a motor is started to finally drive a medicine taking groove to move to the position below a push rod base, and the second hydraulic telescopic rod is started to drive the mounting frame to move upwards. And the push rod of the injector can be driven to move upwards to extract the liquid medicine in the propofol container, so that the time for extracting the propofol is saved, and meanwhile, the manpower of medical personnel is also saved.

The invention provides a detection method for related substances in a dotegravir-emtricitabine-propofol tenofovir compound preparation. The detection method comprises the following steps of: detecting the related substances in the compound preparation; specifically, the invention provides a high performance liquid chromatography detection method for related substances in a dotegravir-emtricitabine-propofol tenofovir compound preparation, and the method can realize rapid, simple and accurate separation and detection of related substances from dotegravir sodium, emtricitabine and propofol tenofovir fumarate. Therefore, the quality control requirements of the dotegravir-emtricitabine-propofol tenofovir compound preparation can be met.

The invention belongs to the technical field of chemical medicines, and particularly relates to a crystal form of a salt of a propofol derivative as well as a preparation method and application thereof. The invention provides a crystal form of a compound A or a hydrate, an organic solvate or an organic solvate of the hydrate of the compound A with a structure shown as a formula I. The stability and the safety of the crystal form are greatly improved, and the crystal form has important significance for improving the medicine quality. # imgabs0 #

The present application provides a propofol analogue, a preparation method thereof and application thereof in non-narcotic field. The propofol analogue has a structure as shown in general formula (G). The propofol analogue of the present application can greatly reduce or eliminate the affinity to GABA receptor, i.e. weaken or eliminate the narcotic property. It targets specific targets and shows effects in improving sleep, regulating blood pressure, relieving vomiting, resisting depression, protecting heart and brain, etc. (G).

The invention relates to a pharmaceutical composition for intraoperative brain protection in shoulder arthroscopy surgery. The pharmaceutical composition comprises midazolam, propofol, sufentanil, succinylcholine and atracurium besylate. According to the invention, rScO2 can be improved, the risk of cerebrovascular events can be reduced, but no obvious influence is generated on the circulation stability in the operation of a patient, the postoperative cognitive impairment and the like.

The invention relates to application of propofol in preparation of a medicine for treating autism, and belongs to the technical field of biological medicine. Researches find that propofol can reduce repetitive self-combing behaviors of gene knockout mice and repetitive behaviors of autistic mice; the social ability and the social novelty of the gene knockout mouse can be improved, the social behavior disorder of the autism mouse is improved, and the function of treating the autism is achieved. The drug selection is provided for clinical treatment of autism, and the application range of propofol is also enriched.

Abstract: A piperazine-substituted phenol derivative having the structure represented by formula (I) is provided. This compound not only has good salt-forming properties and excellent water solubility to meet pharmaceutical requirements, but also has a low minimum effective dose of anesthetics, rapid onset of action, and rapid recovery. This overcomes the drawbacks of prodrugs and lipid emulsion formulations of propofol and ciprofol, and is expected to be used in the preparation of drugs with sedative, hypnotic, and / or anesthetic effects and drugs for controlling status epilepticus. TIFF2025535407000076.tif41170

The invention relates to the technical field of biochemical detection, in particular to a pretreatment method of a propofol-containing sample, a propofol detection method and a kit. The pretreatment method of the propofol-containing sample comprises the following steps: providing the propofol-containing sample; the method comprises the following steps: adding porous polymer lipophilic magnetic beads into a sample, carrying out adsorption treatment, and then carrying out leaching treatment by using water and a methanol solution in sequence to obtain a propofol-magnetic bead compound; and eluting the propofol-magnetic bead compound by using an ammonia water methanol solution to obtain a sample to be detected. The pretreatment method provided by the invention is simple in process and low in cost, the to-be-detected sample containing propofol can be efficiently obtained, and the to-be-detected sample containing propofol can be subsequently used for high-sensitivity detection of propofol by an ion mobility spectrometry technology, so that the pretreatment method has a very good application prospect in the field of propofol detection.

An antibody for binding propofol is provided. Also provided is an immunoassay for assaying propofol and an immunobiosensor for rapid, point-of-care of propofol.

The invention relates to the technical field of knowledge bases, in particular to an anesthetic dosage prediction method and system based on machine learning, and the method comprises the following steps: obtaining preoperative genome data, metabonomics data, intraoperative real-time vital sign data and operating room environment data of a patient, the genome data comprises CYP450 enzyme gene polymorphism data, and the metabonomics data comprises CYP450 enzyme gene polymorphism data; the metabonomics data comprises propofol metabolite concentration data, and the intraoperative real-time vital sign data comprises a BIS value, an MAP value and an HR value; according to the method, a dynamic hypergraph model containing drug nodes, gene nodes, metabolite nodes and environment nodes is constructed, the drug nodes and the gene nodes are connected through hyperedge to represent the regulation and control effect of drug metabolism genes on drug metabolism, the anesthesia safety and effectiveness can be improved, and the urgent clinical requirements for personalized and precise anesthesia are met.

The invention relates to a transmission desorption electrospray low-pressure ion mobility spectrometry which comprises a transmission desorption electrospray ion source, an interface electrode and a low-pressure ion migration tube, the interface electrode is a metal sheet electrode with a through hole in the center, and the transmission desorption electrospray ion source is connected with the low-pressure ion migration tube through the interface electrode. The ion mobility spectrometry can realize efficient desorption spray ionization of substances difficult to volatilize in the detection process, the sample detection process is simplified, the working air pressure is lower than the atmospheric pressure, the detection sensitivity can be improved, furthermore, the ion mobility spectrometry is provided with a desolvation area and is combined with desolvation gas, the detection sensitivity can be further improved, and the detection accuracy is improved. High-sensitivity detection of anesthetic drugs such as propofol, etomidate, fentanyl and the like in blood can be realized through transmission-type desorption electrospray and low-pressure ion mobility spectrometry.

The invention discloses a propofol-metoprolol twin drug as well as a preparation method and application thereof, the propofol-metoprolol twin drug is formed by connecting propofol and metoprolol, and the propofol-metoprolol twin drug is named as WSW-E01-166-P. According to the present invention, the WSW-E01-166-P can achieve the deanesthesia effect, and has good drug stability; the compound has relatively high inhibition efficiency on ICa-L, and shows an anti-arrhythmia effect in a barium chloride induced ventricular arrhythmia rat model. The novel twin drug WSW-E01-166-P disclosed by the invention has relatively good performance in the aspects of IVAs resistance, pharmacokinetics, toxicology and the like, and is greatly helpful for later promotion of entering a phase I clinical research process.

The invention provides an emtricitabine, propofol and tenofovir compound tablet and a preparation method, the emtricitabine, propofol and tenofovir compound tablet comprises a tablet core, the tablet core comprises 300-330 parts of first particles, 20-40 parts of emtricitabine and 3-5 parts of a lubricant, wherein the first particle is prepared from 28 parts of tenofovir alafenamide hemifumarate, 160 to 180 parts of emtricitabine, 85 to 90 parts of a filling agent, 25 to 30 parts of a disintegrating agent and 3 to 5 parts of a lubricating agent, and the particle size D90 of the first particle is 100 to 300 microns. The emtricitabine-propofol-tenofovir compound tablet prepared by the invention is produced by combining dry granulation with a direct tabletting method, and the existing process is slightly changed, so that the production and processing are convenient; under the condition that the dissolution performance and the mixing uniformity are equivalent to those of commercially available preparations, better storage stability is achieved, especially under the illumination condition.

The invention discloses a plasma metabolism biomarker combination for predicting and intervening propofol-induced respiratory depression, a detection method and application, and relates to the technical field of biological science. According to the method, non-target metabonomics detection is conducted on preoperative plasma of 298 subjects through UPLC-MS, 14-metabolite panels are obtained through machine learning supervised feature screening, a diagnosis model is established through verification of discovery and verification queues, and the prediction AUC of severe respiratory depression reaches 0.86-0.91 (discovery queue) and 0.86-0.91 (verification queue). Mouse in-vivo function verification proves that the key metabolite alpha-linolenic acid obviously improves the respiratory rate, the tidal volume and the minute ventilation volume under two administration paradigms of pretreatment and treatment of a mouse propofol-RD model, shortens the recovery time of righting reflex, has a good safety foundation, and has a good application prospect. Prompt can be converted into a foresight supplement or rapid treatment medication thought in a perioperative period, and a'prediction and intervention 'integrated clinical value is formed.

The invention discloses a nanoprobe for detecting propofol in serum and a portable detection device, and relates to the technical field of biomedical detection.The nanoprobe comprises UCNPs and diazonium salt, and the diazonium salt is formed by reaction of sulfanilic acid and sodium nitrite. According to the nanoprobe, the diazonium salt serves as a recognition unit of propofol, UCNPs serves as an energy donor, luminescence quenching can be caused in the presence of propofol, and rapid, sensitive and visual detection of propofol is achieved through rapid specific response between the diazonium salt and propofol.

The application discloses application of propofol in preparation of a medicine for preventing or treating cognitive dysfunction, and realizes prevention or treatment of cognitive dysfunction by propofol through inhibition of nerve inflammation, reduction of oxidative stress and enhancement of synaptic plasticity, and has advantages of exact curative effect, small side effect, multi-target point intervention and controllable cost, overcomes defects of existing medicines, such as curative effect limitation, obvious side effect and single target point, and realizes timely prevention and treatment of senile cognitive dysfunction.

The invention discloses a propofol drug delivery system and method based on appreciation electroencephalogram characteristics, a medium and a product, and relates to the field of intelligent medical systems, and the propofol drug delivery system comprises a signal collection module used for collecting original electroencephalogram signals; the signal processing module is used for mapping the real-time brain function state of the patient to a neural state space containing an appreciation related state and determining a neural state; the prediction calculation module is used for predicting a future evolution trajectory and a state transition probability of a neural state in a neural state space; the control decision module is used for generating a drug administration intervention strategy of propofol by taking the brain function state staying in the target appreciation area as a target; and the infusion execution module is used for adjusting the target control infusion pump according to the administration intervention strategy so as to guide and maintain the appreciation state. By implementing the application, the patient can be prevented from being in a poor sedative state as much as possible, and the operation prognosis effect is optimized.

The invention discloses an application of an alkyl acid compound in preparation of a medicine for regulating ethanol autonomous intake preference. The invention also discloses a pharmaceutical composition for adjusting the ethanol autonomous intake preference, and the pharmaceutical composition comprises the alkyl acid compound or the pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier and / or excipient. The application of the alkyl acid compound in preparing the medicine for adjusting the ethanol autonomous intake preference is provided for the first time, and animal experiments show that single injection of propofol into the tail vein of a mouse can continuously inhibit the ethanol autonomous intake preference of the mouse. The active ethanol intake absolute amount of mice and the relative ethanol intake proportion relative to the water intake amount can be obviously reduced, and the inhibition effect can last for at least 6 days.